Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Adapting The Lung Cancer Symptom Scale (LCSS) To Mesothelioma

P. Hollen, R. Gralla, A. Liepa, J. Symanowski, J. Rusthoven
Published 2004 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
The underpinning conceptual model for the Lung Cancer Symptom Scale (LCSS), an instrument used to assess health‐related quality of life in patients with lung cancer, has been described elsewhere. The patient‐rated scale of the LCSS was modified slightly for patients with mesothelioma (LCSS‐Meso), because no other mesothelioma‐specific instrument was available.
This paper references
10.1016/S0140-6736(95)90462-X
Continuing increase in mesothelioma mortality in Britain
J. Peto (1995)
Food and Drug Administration requirements for approval of new anticancer drugs.
J. Johnson (1985)
10.1378/CHEST.93.1.159
Prognostic factors in diffuse malignant pleural mesothelioma. A study of 167 patients.
E. Chailleux (1988)
10.7326/0003-4819-96-6-746
Diffuse malignant mesothelioma. Prospective evaluation of 69 patients.
A. Chahinian (1982)
Psychological testing (6th edition)
A. Anastasi (1988)
Validation of a quality of life instrument for patients with pleural mesothelioma: Lung Cancer Symptom Scale (LCSS)
PJ Hollen (2001)
10.1007/s005200050244
Normative data and trends in quality of life from the Lung Cancer Symptom Scale (LCSS)
P. Hollen (1999)
10.1002/cncr.11405
Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma
A. Favaretto (2003)
Instruments for clinical health-care research
M. Frank-Stromborg (1997)
Assessing Quality of Life in Patients with Lung Cancer: A Guide for Clinicians
C. Moinpour (1995)
Measurement of quality of life in patients with lung
PJ Hollen
10.1200/JCO.2003.06.122
Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
G. Scagliotti (2003)
10.1200/JCO.1996.14.2.671
Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology.
J. Fetting (1996)
Designing clinical research (2nd edition)
SB Hulley (2001)
10.2307/1269238
Generalized Linear Models
J. H. Schuenemeyer (1992)
An overview of the Lung Cancer Symptom Scale
PJ Hollen (1995)
10.1378/CHEST.116.2.504
Advances in the treatment of malignant pleural mesothelioma.
D. Sterman (1999)
10.1016/0021-9681(87)90011-7
Cancer patients' quality of life over the disease course: lessons from the real world.
V. Mor (1987)
Subjective evaluation in non - small cell lung cancer : comparison of Karnofsky performance status with a patient generated visual analogue scale measuring activity [ abstract ]
PJ Hollen (1985)
10.1378/CHEST.113.1_SUPPLEMENT.66S
A review of chemotherapy trials for malignant mesothelioma.
C. Ryan (1998)
Diagnosing and dealing with multicollinear
MA Schroeder (1990)
10.1016/S0959-8049(05)80262-X
Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale (LCSS).
P. Hollen (1993)
10.1016/S0959-8049(01)81532-X
Health-related quality of life of patients with malignant pleural mesothelioma treated with pemetrexed disodium
R. Gralla (2001)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1097/00000421-198606000-00019
Methodologic guidelines for reports of clinical trials.
R. Simon (1985)
10.1378/CHEST.107.6_SUPPLEMENT.332S
Current approach to malignant mesothelioma of the pleura.
J. Aisner (1995)
Psychometric theory (3rd edition)
JC Nunnally (1994)
10.1200/JCO.2003.05.123
Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study.
K. Fizazi (2003)
Health-related quality of life of patients with malignant pleural mesothelioma treated with pemetrexed disodium [abstract
R Gralla (2001)
Symptom and quality of life advantages for pemetrexed cisplatin versus cisplatin in treatment of malignant pleural mesothelioma [abstract
MJ Boyer (2003)
10.1200/JCO.1988.6.3.527
Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers.
A. Alberts (1988)
10.1177/107327489700400404
Current Therapy for Mesothelioma.
Sugarbaker (1997)
A Phase II trial of pemetrexed in malignant pleural mesothelioma (MPM) patients: clinical outcome, role of vitamin supplementation, respiratory symptoms and lung function
D M Shin
The clinical evaluation of chemotherapeutic agents in cancer
Da Karnofsky (1949)
10.1177/019394599001200204
Diagnosing and Dealing with Multicollinearity
M. Schroeder (1990)
10.1200/JCO.1989.7.8.1157
Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients.
P. Ruffié (1989)
10.1016/S0169-5002(03)91714-4
O-56 Symptom and quality of life advantages for pemetrexed + cisplatin versus cisplatin in treatment of malignant pleural mesothelioma
M. Boyer (2003)
Psychometric theory
J C Nunnally (1994)
10.1016/S0169-5002(00)00179-3
Quality of life in lung cancer patients: as an important prognostic factor.
A. Montazeri (2001)
Quality of life score predicts both response and survival in patients receiving chemotherapy for non-small cell lung cancer
RJ Gralla (1995)
10.1007/BF00365725
Quality of life during clinical trials: conceptual model for the Lung Cancer Symptom Scale (LCSS)
P. Hollen (2004)
10.1016/S0167-8140(00)00158-4
The prognostic impact of quality of life assessed with the EORTC QLQ-C30 in inoperable non-small cell lung carcinoma treated with radiotherapy.
H. Langendijk (2000)
Symptom and quality of life advantages for pemetrexed ϩ cisplatin versus cisplatin in treatment of malignant pleural mesothelioma
M J Boyer
Generalized linear models (2nd edition)
P McCullagh (1989)
A Phase II trial of pemetrexed in malignant pleural mesothelioma (MPM) patients: clinical outcome, role of vitamin supplementation, respiratory symptoms and lung function [abstract
DM Shin (2002)
Benign and malignant mesothelioma
KH Antman (1997)
10.1002/1097-0142(19940415)73:8<2087::AID-CNCR2820730813>3.0.CO;2-X
Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the lung cancer symptom scale
P. Hollen (1994)



This paper is referenced by
10.1177/0269216309346593
Evaluation of quality-of-life measures for use in palliative care: a systematic review
G. Albers (2010)
10.5603/ARM.a2019.0003
Evaluation of the quality of life after surgical removal of lung cancer.
Ewa Szeliga (2019)
10.1007/978-3-319-96244-3
Caring for Patients with Mesothelioma: Principles and Guidelines
M. Hesdorffer (2019)
10.1186/1745-6215-15-367
A multicentre non-blinded randomised controlled trial to assess the impact of regular early specialist symptom control treatment on quality of life in malignant mesothelioma (RESPECT-MESO): study protocol for a randomised controlled trial
Samal Gunatilake (2014)
10.1007/s11864-011-0152-6
Chemotherapy for Malignant Pleural Mesothelioma
L. Garland (2011)
10.3978/j.issn.2072-1439.2013.11.28
Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.
N. van Zandwijk (2013)
10.1136/BMJSPCARE-2011-000020.41
‘It's all bad news’: the first 3 months following a diagnosis of malignant pleural mesothelioma (MPM)
A. Arber (2011)
10.12968/hmed.2017.78.4.219
Palliative care for patients with mesothelioma.
Marianne Tinkler (2017)
10.1007/s13691-017-0281-2
Stepwise increase of MIB-1 index in frequently relapsed malignant peritoneal mesothelioma
S. Isonishi (2017)
10.1002/cncr.22410
The role of 2‐deoxy‐2‐[F‐18]fluoro‐D‐glucose positron emission tomography in disseminated carcinoma of unknown primary site
P. Sève (2007)
Applications Of Continuous-Time Survival In Latent Variable Models For The Analysis Of Oncology Randomized Clinical Trial Data Using Mplus
B. Muthén (2009)
The association between microcytic anemia and spirometric parameters • Endothelial dysfunction in children with clinically stable and exacerbated asthma • Evaluation of the quality of life after surgical removal of lung cancer
Wojciech Jerzy Piotrowski (2019)
10.2196/19180
Advanced Symptom Management System for Patients with Malignant Pleural Mesothelioma (ASyMSmeso): Mixed Methods Study
R. Maguire (2020)
Op 15 oktober 2012 promoveerde Gwenda Albers aan de Vrije Universiteit te Amsterdam op het proefschrift ‘Measuring quality of life and dignity in palliative care research’
G. Albers (2012)
A randomised controlled trial of regular early specialist palliative care on quality of life in malignant pleural mesothelioma – ‘RESPECT-Meso’
F. Brims (2018)
10.1007/s00520-018-4438-0
Efficacy of Pennebaker’s expressive writing intervention in reducing psychiatric symptoms among patients with first-time cancer diagnosis: a randomized clinical trial
Luana La Marca (2018)
10.1186/s41687-019-0122-5
Evaluation of the psychometric properties and minimally important difference of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM)
T. Mendoza (2019)
10.1111/j.1365-2354.2009.01162.x
Living with mesothelioma. A literature review.
S. Moore (2010)
10.1007/978-3-319-96244-3_13
Palliative Care Services for Mesothelioma Patients
S. Cunningham (2019)
10.21037/TLCR.2018.07.08
The use of patient-reported outcome measures (PROMs) in the management of malignant pleural mesothelioma: a descriptive literature survey
Youssef Ben Bouazza (2018)
10.1001/jamaoncol.2016.3049
Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1–Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial
P. Szlosarek (2017)
10.1007/s10549-015-3420-5
Determining issues of importance for the evaluation of quality of life and patient-reported outcomes in breast cancer: results of a survey of 1072 patients
P. Hollen (2015)
10.1016/J.CTRV.2007.07.012
Assessment of tumor response in malignant pleural mesothelioma.
G. Ceresoli (2007)
10.1590/S0104-11692012000200025
Evaluation of quality of life in a palliative care context: an integrative literature review.
Fernanda Ribeiro Correia (2012)
10.1002/pon.3162
‘It's all bad news’: the first 3 months following a diagnosis of malignant pleural mesothelioma
A. Arber (2013)
10.1136/thoraxjnl-2018-212380
Early specialist palliative care on quality of life for malignant pleural mesothelioma: a randomised controlled trial
F. Brims (2019)
10.1016/S1470-2045(18)30193-1
NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial.
V. Gregorc (2018)
10.2147/TCRM.S1603
Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma
Ranjit K Goudar (2008)
10.1016/J.CCM.2006.01.004
Management of malignant pleural mesothelioma.
S. West (2006)
Malignant pleural mesothelioma : recognising an unmet need
Samal Gunatilake (2018)
10.1517/14656566.7.7.917
Pemetrexed in thoracic cancer
H. Goeminne (2006)
10.1158/1078-0432.CCR-18-2860
Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial
G. Eberst (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar